Agenus Inc (AGEN) - News Archive

Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual MeetingLEXINGTON, Mass. - Agenus Inc. (Agenus), a leading developer of immunological agents for cancer treatment, has announced...

Breakthrough Data on Botensilimab/Balstilimab in MSS CRC to be Presented at ASCO 2024 Agenus Inc. (Nasdaq: AGEN), a recognized leader in the development of innovative immunological therapies to combat cancer, has announ...

In an exciting development for the field of cancer treatment, Agenus Inc., a prominent biotechnology company specializing in groundbreaking immunological agents, has announced its plans to conduct a Type B End-of-Phase...

Agenus Inc., a renowned developer of innovative immunological agents for cancer treatment, has recently announced the selection of its botensilimab and balstilimab combination data for presentation at the 2024 Annual Me...